One shot may be enough: HPV vaccine study could change guidelines
NCT ID NCT07314307
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a single dose of the HPV vaccine (Gardasil 9) can protect young women from HPV infection. Over 150,000 women in Sweden are participating, receiving one vaccine dose along with routine screening. The goal is to see if one dose is effective enough to help eliminate HPV and reduce cervical cancer risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gardasil 9 (HPV vaccine)
- What this could lead to
- If one dose works as well as the full series, it could simplify HPV vaccination, making it easier and cheaper to prevent cervical cancer.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be less definitive. The study only follows women for 3 years, so long-term protection is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCIDENT HPV16, 18, 31, 33, 45, 52 OR 58 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karolinska University Hospital
Stockholm, Sweden